, however, might suffer from HBV reactivation. The aim of this study was to assess HBV reactivation in HCV-coinfected inactive HBV carriers following IFN/RBV. Methods: A total of 32 HBV carriers with ≤4 log 10 copies/ ml HBV DNA and with chronic hepatitis C were consecutively evaluated; 22 (16 men, median age 52 years and 11 with cirrhosis) received RBV associated to either standard IFN (n=14) or pegylated (PEG)-IFN-α2b (n=8) for 24 or 48 weeks, according to HCV genotype. Serum alanine aminotransferase (ALT), HBV DNA (lower limit of quantification 2,000 copies/ml) and HCV RNA (limit of detection 25 IU/ml) were evaluated every 3-6 months during the study period.
Background: Interferon (IFN) combined with ribavirin (RBV) is an effective therapy for hepatitis C virus (HCV)-infected patients. Those who are coinfected with hepatitis B virus (HBV), however, might suffer from HBV reactivation. The aim of this study was to assess HBV reactivation in HCV-coinfected inactive HBV carriers following IFN/RBV.
Methods: A total of 32 HBV carriers with ≤4 log 10 copies/ ml HBV DNA and with chronic hepatitis C were consecutively evaluated; 22 (16 men, median age 52 years and 11 with cirrhosis) received RBV associated to either standard IFN (n=14) or pegylated (PEG)-IFN-α2b (n=8) for 24 or 48 weeks, according to HCV genotype. Serum alanine aminotransferase (ALT), HBV DNA (lower limit of quantification 2,000 copies/ml) and HCV RNA (limit of detection 25 IU/ml) were evaluated every 3-6 months during the study period.
Results: Nine (41%) patients had a sustained virological response (SVR). In 3 patients (14%; 1 SVR and 2 nonresponders) serum HBV DNA increased to >4 log 10 copies/ml (range 5.2-6.5 log 10 copies/ml); however, these patients had no ALT flare either on treatment (n=2) or off treatment (n=1). During follow-up, 8 (36%) treated patients and 4 controls lost serum hepatitis B surface antigen (HBsAg; annual rate 6.5% versus 6.9%; P-value non-significant), whereas 4 and 2 patients seroconverted to antibodies against HBsAg, respectively. Hepatocellular carcinoma developed in 1 patient with SVR and 1 nonresponder under nucleoside therapy for HBV, both with cirrhosis. No patient clinically decompensated. Conclusions: Inactive HBV carriers coinfected with HCV might achieve an SVR following IFN/RBV. Combinationtherapy carries a low risk of on-and off-treatment HBV reactivation and does not prevent HBsAg seroclearance.
Hepatitis B virus (HBV) and hepatitis C virus (HCV)
are the most common etiologic factors of chronic liver disease and a major cause of anticipated liver-related mortality worldwide [1, 2] . Special populations might have concurrent infection with both viruses, defined by the presence of both serum hepatitis B surface antigen (HBsAg) and HCV RNA, as often seen in areas with a high prevalence of HBV infection. Although the rate of HBV-HCV coinfection varies according to geographical areas, it is probably inflated by the non-prospective enrolment of patients [3] [4] [5] , therefore raising excessive concerns related to the more severe course of HBV-HCV coinfection compared to infection with either virus [1, [6] [7] [8] [9] [10] [11] [12] . Interferon (IFN)-based treatment is of established efficacy and safety in HCV-monoinfected patients, with convincing evidence that virus eradication prevents liver-related complications [13] [14] [15] ; however, the same is not true for HBV-HCV-coinfected patients [16, 17] . Indeed, the latter patients, have been invariably excluded from registration trials of IFN treatment, primarily on the basis of the assumption that the interaction between the two virus agents might lower the efficacy endpoint of the studies. This opinion has been challenged by two studies reporting similar rates of sustained virological response (SVR) in both coinfected and monoinfected HCV patients [18, 19] . Another reason for excluding coinfected patients from registration trials of IFN-based therapy were the scattered reports Introduction of HBV reactivation occurring in HCV-coinfected patients treated with IFN [20] [21] [22] [23] , probably as a consequence of an unbalanced HBV replication caused by treatment-related suppression of HCV, though a direct immunomodulatory effect of IFN might also be advocated for either on-or off-therapy reactivation of HBV [24] . Mitigating these concerns about the use of IFN in HBV-HCV-coinfected patients, is the well established use of IFN for suppressing HBV, resulting in one-third of patients with chronic hepatitis B achieving a longterm response [25] [26] [27] [28] . To gain more insights into the safety and efficacy of IFN/ribavirin (RBV) therapy for HCV in HBV carriers, we prospectively studied 22 HCV-coinfected inactive carriers of HBV who were followed off-therapy for an average of 5 years.
Methods

Study design
This was a prospective open-label study aimed at evaluating the safety and efficacy of IFN/RBV therapy in inactive carriers of HBV who were coinfected with HCV. The study was approved by the internal review board of the Institutional Review Board of the Department of Internal Medicine, University of Milan, Milan, Italy. The primary endpoint of the study was to assess the rate of HBV reactivation defined as HBV DNA increase to >4 log 10 copies/ml during and off treatment. Secondary endpoints were the rates of sustained clearance of HCV RNA (SVR), clearance of serum HBsAg, antibodies against HBsAg (anti-HBs) seroconversion, and liver-related complications such as clinical decompensation and hepatocellular carcinoma (HCC).
Patients
Between January 2000 and January 2003, all inactive carriers of HBV with serum HCV RNA seen at the Liver Unit, Maggiore Hospital in Milan, Italy, were consecutively evaluated for treatment with IFN/RBV.
Patients were recruited if they fulfilled the following criteria: at least 1 year positivity for serum HCV RNA by reverse transcriptase (RT)-PCR, serum HBsAg and antibodies against hepatitis B e antigen (anti-HBe) with ≤4 log 10 copies/ml HBV DNA in at least two determinations during the year preceding enrolment; a liver biopsy performed in the pre-enrolment year, consistent with chronic hepatitis C; alanine aminotransferase (ALT) levels >1.5 the upper limit of normal (ULN); and no previous treatments with antivirals.
Patients were excluded if they had serum hepatitis D virus (HDV) or HIV, decompensated liver disease, other causes of liver disease, drug dependence, >40 g/ day alcohol intake or HCC. Patients with poorly controlled diabetes, severe depression, autoimmune diseases or concomitant malignant neoplastic diseases were also excluded. All patients gave their written informed consent to receive therapy and gave permission for the use of their medical records.
Treatment and follow-up
All patients received the current standard of care for chronic hepatitis C [29, 30] All patients were evaluated every 4 weeks during the treatment period with liver function tests and clinical examinations. PEG-IFN was reduced to 1 mg/kg per week whenever neutrophil count decreased <0.75×10 9 cells/l, whereas it was withdrawn when neutrophil count was <0.50×10 9 cells/l. RBV dose was tapered by 200 mg/day when haemoglobin decreased <100 g/l, whereas it was discontinued in patients with <85 g/l haemoglobin. Serum HCV RNA was assessed at baseline and weeks 4, 12, 24 and 48 during treatment and at weeks 4, 12 and 24 post-treatment. HCV was genotyped by nested RT-PCR at baseline. Serum HBV DNA was assessed at baseline and weeks 4, 12, 24 and 48 during treatment and at weeks 4, 12 and 24 of follow-up. HBV DNA was subsequently tested every 6 months until the end of follow-up. HBsAg and antiHBs were tested at weeks 24 and 48 of treatment, and subsequently every 6 months.
Serum assays
Serum ALT and aspartate aminotransferase (AST) activities were measured by an automated method at 37°C (normal value ≤37 IU/l). Commercially available enzyme immunoassays were used to determine serum HBsAg, anti-HBs, serum hepatitis B e antigen (HBeAg), anti-HBe, HIV and HDV. Serum HBV DNA was measured by a commercially available test (Versant™ HBV DNA 3.0 Assay; Bayer Healthcare, Tarrytown, NY, USA) with a sensitivity limit of 2,000 copies/ml (3.3 log 10 copies/ml). HCV was genotyped by nested RT-PCR at baseline, using universal biotinylated primers in the 5′ non-coding region (Line Probe Assay, INNO-LIPA HCV 2; Innogenetics, Zwijndrecht, Belgium). Serum HCV RNA was assessed by in-house nested RT-PCR using specific primers from the 5′ non-coding region, at baseline and during treatment at weeks 4, 12, 24 and 48, and after therapy at weeks 4, 12 and 24. The sensitivity limit of the assay was approximately 25 IU/ ml HCV RNA. Serum HCV RNA was quantified by Versant™ HCV RNA 3.0 assay (bDNA 3.0), with a sensitivity limit of 615 IU/ml (2.8 log 10 copies/ml) and a dynamic range from 615 to 7,700,000 IU/ml.
Diagnosis and staging of liver disease
Liver biopsies were performed in all patients with a 16 gauge Tru-Cut needle (Uro-Cut 16 G; TSK, Tokyo, Japan) and read by a single liver pathologist (MFD). Liver biopsies were considered to be adequate for staging fibrosis if they were longer than 15 mm or included >12 portal tracts. The severity of hepatic inflammation was evaluated by the Ishak score in separate reports for grading and staging [31] . The maximum score for grading was 18, ranging from 0 to 4 for piecemeal necrosis, focal necrosis and portal inflammation, and from 0 to 6 for confluent necrosis. The score for staging ranged from 0, representing no fibrosis, to 5, representing incomplete cirrhosis, and 6, representing cirrhosis.
Statistical analyses
Data were expressed as counts and percentages for categorical variables and as medians and ranges for discrete variables. The significance of differences in the distribution of quantitative and categorical variables was assessed with Student's t-test, Fisher's exact test or the Wilcoxon rank-sum test. All P-values were two-tailed and a level of 0.05 was considered statistically significant. The probability of HBsAg loss/ anti-HBs seroconversion was assessed by the KaplanMeier method. The difference between the cumulative curves was tested by the log-rank test. Using time-dependent multivariate analysis, independent predictors of HBsAg loss/anti-HBs seroconversion were looked for among the following variables: age, sex, staging (cirrhosis versus non-cirrhosis), HCV genotype (1 versus non-1), duration of liver disease and IFN therapy (yes versus no). Cox's regression model was used for univariate and multivariate analysis of predictors of HBsAg loss/anti-HBs seroconversion. Statistical analysis was performed with STATA (Stata Statistical Software Release 7.0; Stata Corporation, Collage Station, TX, USA).
Results
During the study period, 32 patients who met the inclusion criteria were consecutively evaluated for anti-HCV treatment. Ten patients were left untreated because of either contraindications to IFN-based treatment (n=6) or refusal (n=4), whereas 22 patients gave their consent to receive anti-HCV therapy (Table 1) . Treatment was discontinued prematurely in one patient because of erythroid hypoplasia that required blood transfusion at week 16 of therapy, and in another patient because of skin infection at the site of injections (week 40). Serum HBV DNA flared to >4 log 10 copies/ml in 2 (9%) patients during treatment. In one patient in whom HCV RNA became undetectable at week 12, serum HBV DNA rose from pretreatment values of 3.8 log 10 copies/ml to 6.5 log 10 copies/ ml, but without any ALT increase. Table 1 . Demographic, clinical and virological characteristics of the HBV-HCV-coinfected patients enrolled in the study a <3.3 log 10 copies/ml. ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; NS, non-significant.
In this patient, the HBV DNA levels became undetectable by non-PCR assay at week 24, and remained persistently undetectable during the treatment period and post-treatment follow-up ( Figure 1A ). In the other patient with a non-response to IFN/RBV therapy, HBV DNA flared at week 12 from undetectable levels to 5.5 log 10 copies/ml, remaining persistently >5 log 10 copies/ml during follow-up, thus requiring treatment with lamivudine 100 mg/daily ( Figure 1B ). Another patient with undetectable HBV DNA at baseline had a <4 log 10 copies/ml flare of HBV DNA at week 12 of treatment which lasted for 12 weeks. The other 19 inactive HBV carriers showed no serum HBV DNA changes during treatment. One (5%) HCV non-responder, however, had a transient increase of serum HBV DNA to 5.2 log 10 copies/ml 3 months after the end of treatment that subsequently returned to persistently undetectable levels during follow-up ( Figure 1C (Table 3) . Among 14 patients treated with standard IFN, 4 (29%) had an SVR. During post-treatment follow-up, 7 patients (2 SVR) lost serum HBsAg, whereas one with persistent HBsAg had an HBV DNA breakthrough 
Discussion
Severe and potentially lethal reactivation of HBV has been reported in immunocompetent inactive carriers
Before treatment
Follow-up Patient HBV DNA, HCV RNA, HBV DNA, number Cirrhosis log 10 copies/ml log 10 IU/ml ALT, IU/l HCV genotype log 10 copies/ml SVR ALT, IU/l HBsAg Anti-HBs of HBV undergoing anticancer chemotherapy with cytostatic drugs or immunosuppressants [32] . Reactivation of HBV has been also reported in some immunocompetent HCV-coinfected patients with chronic HBV infection undergoing IFN-based therapies, albeit without serious clinical sequelae [18] . The strength of our study was the selection of inactive carriers of HBV with concurrent chronic hepatitis C infection, based upon strict laboratory criteria, that is, a ≤4 log 10 copies/ml threshold instead of ≤ 5 log 10 copies/ml, as indicated by the AASLD recommendations [33] . These patients did satisfactorily respond to IFN-based therapy, showing a low risk of HBV reactivation either during or off therapy, which in all cases was uneventful. Indeed, only 2 (9%) patients, had an HBV DNA breakthrough >4 log 10 copies/ml during IFN/RBV treatment, whereas another patient had a transient HBV DNA increase, 3 months after treatment cessation. Interestingly, HBV reactivation occurred independently on the achievement of an SVR, was not associated to an ALT flare (that is, ALT>10×ULN) and, ultimately, only one patient required anti-HBV therapy with lamivudine, which at that time was the standard of care for HBV patients not responding to IFN. Our findings contrast, but do not completely contradict, previous reports that suppression of HCV by IFN/RBV therapy might result in an increased risk of reactivation of a concurrent HBV infection either during or off anti-HCV treatment [18] [19] [20] [21] [22] [23] . The reports of HBV reactivation following IFN/RBV therapy in HBV carriers with concomitant HCV infection were indeed conducted in highly viraemic HBeAg seropositive carriers, mostly infected perinatally, who are relatively immunotolerant against virus replication. Our study, instead, focused on inactive carriers of HBV infection, mostly infected during childhood, with an immune system skewed towards HBV suppression rather than toward cytolitic clearance of infected hepatocytes [34] . In patients with an HBeAg-negative chronic hepatitis B with <20,000 IU/ml HBV DNA and persistently normal ALT, cytolitic clearance of HBV-infected hepatocytes rarely occurs [35] .
Consistent with our observations were two recent studies in Europe [36, 37] that described a small number of inactive HBV carriers coinfected by HCV who, during IFN therapy, had an HBV reactivation (that is, >4 log 10 copies/ml) in 22% and 8% of the cases, respectively, not accompanied by an ALT flare. Conversely, Liu et al. [19] reported an HBV DNA flare in one-third of such patients at the end of either treatment or follow-up, however, without specifying the peak levels of serum HBV DNA.
Analogous with our observation, the few cases of HBV reactivation reported in those studies occurred independently of the outcome of IFN/RBV therapy, suggesting independence of serum HBV DNA fluctuations from HCV RNA replication. These findings notwithstanding, the pathogenic role of the host immunity in the HBV flares during IFN therapy remains elusive [24, 38] . A recent report of high rates of HCV clearance in patients with a severe hepatitis caused by superinfection with HBV emphasizes how both virus interference and immune clearance of virus infected liver cells are important in the outcome of viral hepatitis [39] .
Another interesting finding of our study is the rate of serum HBsAg clearance that apparently was not compromised by IFN/RBV therapy. We acknowledge that HBsAg seroclearance could spontaneously occur in inactive carriers of HBV [40] , although it was also reported in patients with active hepatitis B following IFN or nucleoside/nucleotide analogue therapy [25] [26] [27] 41] ; however, we still think that HCV with active HBV coinfection should be further investigated to establish whether anti-HCV treatment with IFN does enhance HBsAg seroclearance. Indeed, in our study, HBsAg seroclearance occurred as frequently in the untreated patients as in the treated patients, and inactive carriers of HBV have high chances of spontaneous HBsAg seroclearance compared with patients with active HBV infection undergoing treatment with IFN [18, 19, 22, 23] .
Considering all the caveats for the limited sample size of our study, the SVR rates achieved in patients treated with IFN/RBV, that is, 31% of patients infected with genotype 1/4 and 56% of those infected with genotype 2, compare well with previous reports in similar patients [18, 22, 23, 36] , despite the high prevalence (50%) of patients with cirrhosis. Indeed, cirrhosis is a well recognized moderator of treatment outcome that could have accounted for the low rates of SVR in our study compared with registration trials in which HCV-monoinfected patients with cirrhosis were underrepresented (<10%) [42] [43] [44] [45] .
In conclusion, IFN/RBV not only was an effective anti-HCV therapy in inactive carriers of HBV who were concurrently coinfected by HCV, but it was also associated with a low risk of HBV reactivation that was transient and uneventful in all cases.
